Curanex Pharmaceuticals Inc (NASDAQ:CURX – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totaling 5,195 shares, an increase of 68.5% from the September 30th total of 3,084 shares. Currently, 0.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 28,196 shares, the days-to-cover ratio is currently 0.2 days.
Curanex Pharmaceuticals Stock Performance
Shares of CURX opened at $5.85 on Tuesday. Curanex Pharmaceuticals has a fifty-two week low of $3.58 and a fifty-two week high of $13.80. The firm has a 50 day moving average price of $4.74 and a 200-day moving average price of $6.15.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Curanex Pharmaceuticals in a research note on Tuesday, October 27th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has a consensus rating of “Sell”.
View Our Latest Stock Analysis on CURX
About Curanex Pharmaceuticals
Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections.
Further Reading
- Five stocks we like better than Curanex Pharmaceuticals
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
Receive News & Ratings for Curanex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curanex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
